Ixoten

Trofosfamide (Ixoten; Baxter Oncology, Germany) is an alkylating agent that, as with other oxazaphosphorine derivatives, has to… (More)

GOALS OF WORK There is a need for an effective and nontoxic chemotherapy for palliative indication in non-Hodgkin's lymphoma (NHL… (More)

Comparison of pharmacological properties of commercial, racemic trofosfamide (Ixoten) and its dextrorotatory and levorotatory… (More)

As a result of traumata, cancer or chemical poisoning the level of acute-phase proteins released by the liver undergoes a… (More)

Urotoxic side effects, especially hemorrhagic cystitis, have so far been a limiting factor in the therapeutic use of… (More)

Clinical experience with Ixoten (trofosfamide), a derivative of cyclophosphamide, is reported in 29 patients with malignant… (More)

In an open multicenter phase III trial, prophylaxis of the urinary tract with sodium 2-mercaptoethanesulfonate (Mesnum) was… (More)

The efficacy of trofosfamide (Ixoten; Noristan), a derivative of cyclophosphamide, was investigated in 76 patients. Those with… (More)

A bladder carcinoma developed in a 40-year-old man who was being treated with trofosfamide (Ixoten), a cyclophosphamide… (More)

Cytostatic therapy under conditions of "partial synchronisation" is reported. 12 patients with extensive metastases of malignant… (More)